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ABSTRACT
Treatment of colorectal metastatic cancer is still chal-
lenging, despite recent improvements in chemotherapy.
A genetic cancer profile, such as the KRAS (Kirsten rat
sarcoma) gene status, plays a key role in individualized
tailored therapy. Molecular targeted therapy added to neo-
adjuvant chemotherapy can achieve a better pathological
response and prolong survival. Pathological complete re-
sponse of colorectal cancer stage IV is rare. A 47-year-old
female patient presented with rectal adenocarcinoma and
three liver metastases (cT3d/4, N2, Ml). After seven cy-
cles of Bevacizumab and CAPOX in neoadjuvant setting,
we noted more than 70.0% regression of metastases and
complete regression of the primary tumor. We performed
low anterior resection of rectum and synchronous subseg-
mental resection of S3, because the other two lesions were
not detectable. Pathology revealed complete response of
the primary and also secondary tumors. After 8 months,
diagnostic tests did not show any sign of recurrence and
the remaining liver lesions disappeared. Colorectal cancer
is a heterogeneous disease and it is necessary to identify
patients who are at-risk of recurrence and suitable for neo-
adjuvant therapy. Genetic biomarkers play an important
role in metastatic colorectal cancer treatment. Because of
the mutated KRAS gene, Bevacizumab was added to cyto-
toxic therapy achieving a complete pathological response
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of primary tumor and metastasis. This case is unique be-
cause all reported cases with similar results, described
staged surgery and one of reverse staged surgery, but with
similar results. This neoadjuvant therapy has extraordinary
results for colorectal cancer stage IV and can help disease-
free and long-term survival.
Keywords: Bevacizumab; KRAS (Kirsten rat sar-
coma) gene mutation; Metastatic colorectal cancer; Patho-
logical complete response; Vanishing metastases.
INTRODUCTION
Colorectal cancer is a very common malignancy and
a significant health problem [1]. At the time of diagnosis,
almost 25.0% of patients have synchronous metastases,
and up to 50.0% will experience metastases. The liver
is certainly the most common site for metastasis to oc-
cur, and about four-fifths of the patients have isolated
metastatic disease in the liver [2]. However, a minority of
these are initially eligible for surgery. Despite the modern
improvement of cancer therapy [3], treatment of meta-
static colorectal cancer is still challenging, especially in
synchronous presentation. Long-term survival is poorer
than in patients with metachronous metastases [4]. In the
past decade, some neoadjuvant therapies have improved
treatment of stage IV colorectal cancer [5]. Besides the
radio and chemotherapy, newly designed biological agents
have shown great advance in the management of colorectal
disease, particularly in the neoadjuvant setting [6-8].
Because of the different pathways in tumor genesis
and tremendous heterogeneity [9], it is necessary to stratify
every single neoplastic process. Molecular targeted therapy
is based on the specific genetics of every neoplastic pro-
cess which implies individualized treatment according to




such as the KRAS (Kirsten rat sarcoma) gene mutation, is
evaluated in determining molecular targeted therapy [6].
Neoadjuvant chemotherapy response is very impor-
tant for disease-free and overall survival, and in the era of
effective chemotherapy, various criteria for tumor response
are established [10]. A complete pathologic response of
both primary and secondary tumors, is extremely rare
[11]. We present a case of individualized management of
metastatic colorectal cancer with a complete pathological
response of both primary and secondary tumors.
Case Presentation. A 47-year-old female with a few
months history of abdominal pain and bloody stools was
admitted to our clinic in April 2017. Colonoscopy revealed
a large circumferential tumor, 7 cm from the anal verge,
and pathological examination of biopsied material diag-
nosed adenocarcinoma [Figure 1(a)]. Carcinoembryonic
antigen (CEA) was 16.3 μ/L and carbohydrate antigen
19-9 (CA19-9) was in the normal range.
Computerized tomography (CT) of the abdomen
and pelvis showed three metastatic lesions in the liver: in
segment three (S3) 42 χ 33 mm [Figure 1(b)], in S7 two
lesions, one superficial 31 x 19 mm [Figure 1(c)], and
the other 33 x 33mm [Figure 1(d)], inseparable from the
right hepatic vein; the rectal tumor was in the middle and
proximal part of the rectum and distal part of the sigmoid
colon, 10 cm in length, 7 cm from the anal verge, calculated
on CT scans [Figure 1(e) and (f)]. Clinical tumor-node-
metastasis (TNM) classification was T3d/4, N2, Ml, and
one lesion of 3 cm was also detected in the spleen but with
an unclear diagnosis. The multidisciplinary team decided
to start treatment with preoperative chemotherapy. Due to
the prediction of bowel obstruction, we first performed a
bipolar colostomy.
The mutation was detected by genetic analysis of
biopsied tumor tissue that was based on real-time poly-
merase chain reaction (PCR). The detected mutation was
on codon 13 (G13X) of the KRAS gene, but we were not
able to elucidate the exact mutation type because of the
method limitations. Thus, we excluded the possibility of
Cetuximab according to our national guidelines. In this
situation, we decided to use combined regimen of Oxali-
platin and Capecitabine with the addition of Bevacizumab,
which is the only remaining biological agent for colorectal
liver metastases at our oncological practice. We did not
have the possibility of performing vascular endothelial
growth factor (VEGF) expression on the tumor sample,
so we were unable to determine tumor tissue sensitivity to
Bevacizumab. However, it is widely accepted to include
this medicine in the first line therapy. After four cycles
of neoadjuvant therapy, we confirmed partial regression
on CT scans, according to response evaluation criteria in
solid tumors (RECIST), and continued with three more
cycles because the patient was in good general condition
and therapy was efficient.
In November 2017, CT of the thorax, abdomen,
and pelvis was done and revealed total regression of the
primary rectal tumor [Figure 1 (g) and (h)], and further
regression of metastatic lesions (lesion in S3 was 13 χ 12
mm) [Figure l(i)], superficial lesion in S7 was 11x8 mm
[Figure l(j)], and in S7 lesion near to the right hepatic
vein was 8 x 6 mm [Figure l(k)]. Tumor markers reached
normal values, and the splenic lesion was stable in size.
The patient was prepared for the operation, and in
January 2018, we performed a low anterior resection
of the rectum with total mesorectal excision, colorectal
anastomosis, and synchronous liver resection. During the
operation, we did not find any signs of dissemination in
the abdomen. The rectal tumor was presented as a few
centimeter scar. In the liver, we found only the lesion in
S3, and another two lesions were not detectable either
by palpation or by intraoperative ultrasound. Thus, we
performed only a subsegmental liver resection of S3, and
because the CT scan detected the splenic lesion, we also
performed a splenectomy.
The patient recovered from the operation without
any complication. Pathological examination showed the
complete response of both primary and secondary liver
tumors without any positive lymph node (yTNM8: TO, NO
(0/31), M0). Microscopic findings described only fibrosis
and mucin in rectal tumor residue [Figure 1(1)] and mul-
tiple necrotic nodules surrounded by fibro-vascular septa
in the liver specimen [Figure l(m)]. The splenic tumor
was characterized to be a benign sclerotic vascular tumor.
In the follow-up period after 4 and 8 months we did
not find any sign of malignancy. Four months after the
operation, tumor markers were normal, and we found S3
without recurrence on the CT scan [Figure l(n)] and two
lesions in S7 that are described as fibrotic tissue [Figure
1(o) and (p)]. After 8 months, the CT scan did not show any
sign of focal lesions in the liver and tumor markers were
still in the normal range. Then we performed positron-
emission tomography (PET) and confirmed that the liver
was free of malignancy and pelvis free of recurrent tumors.
The patient is still free of recurrent disease.
DISCUSSION
Today standard therapy for metastatic colorectal can-
cer certainly comprise both surgery and chemotherapy.
Outcomes of surgery alone include death in almost 30.0%
of patients during the first 2 years. Chemotherapy has not
yet achieved a long-term cure [2,4], hence, surgery is still
necessary for cure. With combined treatment, more than
50.0% of the patients can reach a 5-year survival and up
76
BALKAN JOURNAL OF MEDICAL GENETICS
Bulajic P, Bidzic N, Djordjevic V, Ceranic M, Basaric D, Pesic V, Djordjevic-Pesic J
Figure 1. (a): Preoperative histopathology-adenocarcinoma; (b), (c), (d), (e), (f): preoperative CT of primary and secondary tumors;
(g), (h), (i), (j), (k): CT after neoadjuvant therapy; (1), (m): complete pathological response of primary rectal tumor and secondary liver
metastases in S3, respectively; (n), (o), (p): CT shows vanishing liver metastases 4 months after the operation.
to 25.0% 10-year survival [12]. Even then, the recurrence
rate is high, and about 75.0% of all recurrences are seen
in the first 2 years [2].
Chemotherapy can prolong recurrence-free survival
[4,13], increase resectability of liver metastases [14] and




of cytotoxic agents are in use (FOLFOX, CAPOX, FOL-
FIRI, and FOLFOXIRI). New biological therapy added
to cytotoxic regimens may enhance therapeutic efficiency,
especially in the neoadjuvant setting [16,17]. Chemother-
apy, with or without targeted therapy, is recommended
for synchronous colorectal liver metastases because they
have a less favorable cancer biology [13,16] and expected
survival than metachronous, particularly in late metachro-
nous metastases [2].
It is of great importance to identify patients at-risk of
recurrence and the patients who will receive a benefit from
neoadjuvant therapy. Earlier clinical and pathological risk
scores are used to estimate prognosis after surgery and to
evaluate eligibility for surgery [4]. In the era of modern
systemic chemotherapy regimens, these risk scores have
low efficiency in clinical decision-making [18,19].
Colorectal cancer is a heterogeneous disease with
several possible pathways responsible for carcinogenesis
and a lot of genetic mutations. Different genetic and chro-
mosomal alterations are described: microsatellite instabil-
ity, loss of heterozygosity of chromosome 18, mutations
in p53, RAS and RAF mutations (9). Thus, various tumor
biology is possible and subsequently, different responses to
neoadjuvant therapy. Molecular biomarkers are now being
incorporated in risk stratification and treatment decision
due to developing a personalized or individualized treat-
ment [20]. Testing of cancer genetic profile has a leading
role in the new concept of personalized medicine, and
some of these are widely accepted and frequently used in
molecular targeted therapy [21].
Evaluated molecular targeted therapy for metastatic
colorectal cancer includes Bevacizumab and Cetuximab.
Bevacizumab is a monoclonal antibody inhibitor of VEGF,
which is the product of the same-named gene and has a
crucial role in angiogenesis and tumor growth [7,8]. Ce-
tux-imab is a monoclonal antibody inhibitor of epidermal
growth factor receptor (EGFR) which is very effective in
the therapy of KRAS wild-type cancers but with no effect
on KRAS mutations [6,21], except in the specific mutation
on codon 13 (G13D), which is probably associated with
some response to Cetuximab [22]. In the present case, we
detected a mutation on codon 13 but without differentia-
tion of the exact mutation type, and we did not know if
it was a G13D mutation. Even then, the results of recent
studies were not so strong to incorporate the Cetuximab
for G13D, especially in a neoadjuvant setting [22]. We
decided to use cytotoxic neoadjuvant therapy (CAPOX)
and to add Bevacizumab as the only remaining biological
agent for colorectal liver metastases, which were previ-
ously evaluated as a potent neoadjuvant regimen. There is a
possibility for estimation of VEGF expression in the tumor
sample, but in our oncological practice it is not routinely
used for colorectal cancer as the majority of patients have
good therapeutic results [8,16,17]. After seven cycles of
CAPOX and Bevacizumab, we achieved an extraordinary
response: more than 70.0% regression of metastatic lesions
and complete regression of the primary tumor, according
to RECIST. Carcinoembryonic antigen and CA19-9 were
normal. Postoperative histopathology revealed complete
primary and secondary tumor response without any evi-
dence of malignancy [Figure 1(1) and l(m)].
The complete pathological response has been re-
ported, but most of the authors have presented cases with
staged surgery for synchronous metastatic disease and
input neo-adjuvant treatment after resection of the primary
tumor and before resection of secondary tumors [23-25].
In one case, it was even a reverse or liver-first approach
but also achieving complete response in primary and meta-
static tumors [26].
The primary tumor was locally advanced (cT3d/4, N2)
and surgery as a first-line treatment would not be a proper
decision because of the risk of local recurrence. On the
other hand, pelvic radiotherapy has a complete response in
10.0 to 20.0% cases but has many side effects [27]. In this
case, we had to treat both primary and metastatic tumors
and achieving a positive effect on neoadjuvant treatment
we achieved a chance for a synchronous resection.
Vanishing metastases and impossibility to detect liver
lesions intraoperatively after neoadjuvant treatment have
been described. The reason is the same echogenicity of the
lesion and normal liver parenchyma [28]. Concordance
between imaging and pathological examination particu-
larly in bevacizumab-containing neoadjuvant therapy is
poor and so visible lesions on imaging can be without
malignant cells on histopathology [29]. Natural history
of undetectable lesions after neoadjuvant chemotherapy
in case of complete pathological response of the other le-
sions has not yet been elucidated. We performed CT scans,
tumor markers and PET after 8 months and all pointed to
recurrence-free status. Complete disappearance of primary
and secondary lesions makes this case unique.
CONCLUSIONS
There are literature data on similar efficiency of com-
bined cytotoxic and biological therapy, especially in the
neoadjuvant setting, as well as on its impact on long-term
survival. Genetic mutations as biomarkers have a crucial
role in the management of colorectal cancer stage IV, with
KRAS mutation status being significant in the choice of
neoadjuvant molecular targeted therapy. Our study has
shown that Bevacizumab-containing neoadjuvant treat-
ment can have rather promising results for both metastatic
and primary colorectal cancer.
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Pathological complete response is associated with
better overall survival and should be evaluated in future
research. We conclude that modern cancer therapy must be
individualized, multimodal and based on a genetic cancer
profile.
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